New pieces in the puzzle: How does interferon‐β really work in multiple sclerosis?

@article{Mitsdoerffer2009NewPI,
  title={New pieces in the puzzle: How does interferon‐$\beta$ really work in multiple sclerosis?},
  author={Meike Mitsdoerffer and Vijay K. Kuchroo},
  journal={Annals of Neurology},
  year={2009},
  volume={65}
}
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Although the etiology of MS is still unknown, there is good circumstantial evidence that T cells reacting against myelin antigens are key players in the initiation of the pathogenic process. For many years, the major role in the induction of organ-specific autoimmunity was attributed to interferon (IFN)producing T helper 1 (TH1) lymphocytes, as they were found in CNS perivascular… 
CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis
TLDR
Treatment with CpG type A ODN (CpG-A), known to induce high amounts of IFN-α in pDCs, significantly reduced disease severity in EAE, relative to controls and identified a link between TLR9 activation by specific ligands and the induction of tolerance via innate immunity mechanisms.
The immunology of multiple sclerosis.
TLDR
The findings presented here begin to question the exclusivity of an antigen-specific cause and highlight how seemingly distinct immune cell types can share common functions that drive disease.
RhoA Drives T-Cell Activation and Encephalitogenic Potential in an Animal Model of Multiple Sclerosis
TLDR
It is demonstrated that RhoA is a central regulator of several archetypical T-cell responses, and furthermore points toward RHoA as a new potential therapeutic target in diseases such as MS, where T- cell activity plays a central role.
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and CNS inflammation via the aryl hydrocarbon receptor
TLDR
Findings suggest that IFN-Is produced in the CNS function in combination with metabolites derived from dietary tryptophan by the gut flora to activate AHR signaling in astrocytes and suppress CNS inflammation.
Cytosolic RIG-I–like helicases act as negative regulators of sterile inflammation in the CNS
TLDR
RLHs are identified as negative regulators of TH1 and TH17 responses in the CNS, demonstrate a protective role of the RLH pathway for brain inflammation, and establish oligonucleotide ligands of RLHs as potential therapeutics for the treatment of multiple sclerosis.
Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis
TLDR
Phospho-specific flow cytometry can delineate subset-specific cell responses that can act as surrogates for NAb exposure in blood and alter the response in primary cells even at low NAb levels.
Th22 cells are expanded in multiple sclerosis and are resistant to IFN‐β
TLDR
It is reported that similar to Th17 cells, the number of Th22 cells increased in the PB and the CSF of RR MS patients, especially during the active phases of the disease, suggesting that expansion of Th 22 cells in MS could be one of the factors that critically influence resistance to IFN‐β therapy.
Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
TLDR
The findings suggest that interferon-β may mediate some of its therapeutic effects in relapsing-remitting multiple sclerosis through the induction of hepatocyte growth factor by blood monocytes by coupling immune regulation and neuroprotection.
Multiple Sclerosis: Immunopathology and Treatment Update
TLDR
Go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments and present current disease-modifying therapies for the treatment of MS.
...
...

References

SHOWING 1-10 OF 17 REFERENCES
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.
TLDR
Observations suggest an enrichment of both IL-17+CD4+ and CD8+ T cells in active MS lesions as well as an important role for IL- 17 in MS pathogenesis, with some remarkable differences from the experimental autoimmune encephalomyelitis model.
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
TLDR
Increased numbers of IL-17 mRNA expressing MNC in MS are demonstrated with higher numbers in CSF than blood, and with the highest numbers in blood during clinical exacerbations.
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
TLDR
Large-scale analysis of transcripts in MS lesions elucidates new aspects of pathology and opens possibilities for therapy, and results in EAE corroborate the microarray studies on MS lesions.
Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system
TLDR
It is shown that IL-27 receptor–deficient mice chronically infected with Toxoplasma gondii developed severe neuroinflammation that was CD4+ T cell dependent and was associated with a prominent IL-17 response.
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
TLDR
Using passive transfer studies, it is confirmed that these IL-23–dependent CD4+ T cells are highly pathogenic and essential for the establishment of organ-specific inflammation associated with central nervous system autoimmunity.
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.
TLDR
Using a murine model of MS, EAE, it is demonstrated that the Th17-mediated development of autoimmune disease is constrained by Toll-IL-1 receptor domain-containing adaptor inducing IFN-beta-dependent (TRIF-dependent) type I IFN production and its downstream signaling pathway.
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
TLDR
It is shown that the perceived central role for IL-12 in autoimmune inflammation, specifically in the brain, has been misinterpreted and that IL-23, and not IL- 12, is the critical factor in this response.
TH-17 cells in the circle of immunity and autoimmunity
TLDR
New data suggest a dichotomy between CD4+ regulatory T cells positive for the transcription factor Foxp3 and TH-17 cells, whereas IL-6 inhibits TGF-β-driven Foxp 3 expression and together with T GF-β induces TH- 17 cells.
...
...